Cellebrite DI (NASDAQ:CLBT) Announces Quarterly Earnings Results

Cellebrite DI (NASDAQ:CLBT) posted its quarterly earnings data on Thursday. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02, Briefing.com reports. Cellebrite DI had a positive return on equity of 220.14% and a negative net margin of 32.57%. The company had revenue of $89.60 million for the quarter, compared to analyst estimates of $85.34 million. During the same quarter in the previous year, the firm earned $0.03 earnings per share. The business’s revenue was up 25.8% on a year-over-year basis.

Cellebrite DI Stock Down 6.6 %

Shares of Cellebrite DI stock opened at $11.10 on Friday. Cellebrite DI has a 12 month low of $5.45 and a 12 month high of $12.50. The stock has a market cap of $2.29 billion, a PE ratio of -19.14, a price-to-earnings-growth ratio of 1.93 and a beta of 1.51. The business has a fifty day simple moving average of $11.11 and a 200 day simple moving average of $9.91.

Analyst Upgrades and Downgrades

CLBT has been the topic of several research reports. William Blair upgraded shares of Cellebrite DI from a “market perform” rating to an “outperform” rating in a research report on Wednesday, March 13th. JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday. Lake Street Capital began coverage on shares of Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 price target for the company. Bank of America boosted their price objective on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Finally, Craig Hallum increased their price objective on Cellebrite DI from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI presently has an average rating of “Buy” and a consensus target price of $13.17.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.